Market revenue in 2023 | USD 171.7 million |
Market revenue in 2030 | USD 296.7 million |
Growth rate | 8.1% (CAGR from 2023 to 2030) |
Largest segment | Logistics & distribution |
Fastest growing segment | Logistics & distribution |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Logistics & distribution, Storage & retention, Packaging, labeling and blinding, Manufacturing, Comparator sourcing, Other services (solutions, ancillary supply) |
Key market players worldwide | Thermo Fisher Scientific Inc, Catalent Inc, PAREXEL, Almac Group, Piramal Pharma Solutions, DHL Group, FedEx Corp, UDG Healthcare, Marken, Walden Group, PCI Pharma Services |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical trial supply & logistics market will help companies and investors design strategic landscapes.
Logistics & distribution was the largest segment with a revenue share of 25.33% in 2023. Horizon Databook has segmented the China clinical trial supply & logistics market based on logistics & distribution, storage & retention, packaging, labeling and blinding, manufacturing, comparator sourcing, other services (solutions, ancillary supply) covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the lucrative markets for clinical trial supplies players owing to its diverse pool of patients and growing pharmaceutical market. Logistics and supply chain is a major challenge in the country, which is discouraging major biopharmaceutical companies from conducting trials in China.
The country accounted for 34.83% of global clinical trials conducted as of 2020 and exhibited lucrative growth in the past 3 years. The trend is driving the entry of major players such as Catalent Pharma Solutions in China, which is expected to contribute to market growth in the country.
In 2019, Catalent Pharma Solutions, a global clinical trial supplies company, opened 30,000 ft2 Shanghai clinical supply facility located in Tangzhen, which provides customers with a mainland option and supports their need for speed & efficiency in running trials in China, including additional storage capacity, faster local distribution, and service for returns & damage.
Horizon Databook provides a detailed overview of country-level data and insights on the China clinical trial supply & logistics market , including forecasts for subscribers. This country databook contains high-level insights into China clinical trial supply & logistics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account